Hexadrone

Other Names

6-chloro-androst-4-ene-3-one-17b-ol6a-chloro-androst-4-en-17b-ol-3-one6α-chloro-androst-4-ene-3-one-17β-ol

Synopsis

Hexadrone (6-Chloro-androst-4-ene-3-one-17β-ol)

1. Identity: Chemical Name, Origin, and Common Forms

Hexadrone, also known as 6α-chloro-androst-4-ene-3-one-17β-ol, is a synthetic compound that has gained attention in the world of nutritional supplements and sports performance products. It is also rendered in the literature and on product labels as 6-chloro-androst-4-en-17β-ol-3-one, 6-Chloro-andro-4-ene-17 beta-ol-3-one, and sometimes abbreviated simply as Hexadrone. Its PubChem Compound ID is CID 118993568, with the molecular formula C₂₅H₃₅ClO₄.

Though not found naturally in herbs or traditional medicinal plants, Hexadrone is a synthetic compound that has garnered attention in the realm of sports nutrition and bodybuilding supplements. Originally developed as a prohormone, Hexadrone is structurally related to anabolic-androgenic steroids and has been marketed for its potential to promote muscle growth, strength, and improved body composition.

It is a derivative of testosterone, structurally modified with a chloro-group at the 6th position. The 6-chloro modification completely blocks the aromatase enzyme from acting on the molecule, making it impossible for Hexadrone to convert to estrogen, ensuring all gains are free of water retention. Crucially, it lacks the C17-alpha alkylation (a methyl group at the 17th carbon) that is characteristic of most oral steroids, meaning it does not pass through the liver via the same toxic pathway as compounds like Dianabol or Anadrol.

The 6β-Chloro-androst-4-en-17β-ol-3-one isomer is an epimer of Hexadrone, possessing milder properties compared to Hexadrone. The two compounds are thus diastereomers, differing only in the spatial orientation of the chloro substituent at the 6-position.

Common commercial forms and preparations include:

Oral capsule or tablet.
Single-ingredient dietary supplement products formulated around 6-chloro-androst-4-ene-3-one-17β-ol.
Multi-ingredient "stacking" formulations combined with other prohormones or designer steroids, such as formulations documented to include 6α-chloro-androst-4-en-17β-ol-3-one alongside other compounds such as methyldiazirinol; both ingredients are prohormones or designer steroids.

2. Historical and Traditional Context

Hexadrone is not found naturally in herbs or traditional medicinal plants; its history is shaped by the broader context of anabolic agents used to support wellbeing, recovery, and physical performance. It has no documented history of use in any traditional medicine system — Ayurveda, Traditional Chinese Medicine, Western herbalism, or any other — because it is an entirely synthetic, laboratory-produced molecule.

Despite the broad spectrum of adverse effects and legal consequences associated with anabolic-androgenic steroids (AAS), AAS are illicitly marketed and distributed in many countries. To circumvent existing laws, the chemical structure of AAS is modified and these designer steroids are sold as nutritional supplements mainly over the Internet. Hexadrone emerged in this regulatory environment, entering the dietary supplement market in approximately the early-to-mid 2010s as part of a generation of chlorinated and otherwise structurally novel androgens designed to evade scheduling laws that had banned earlier prohormones under the Anabolic Steroid Control Act of 2004.

The Steroid Control Act of 2004 had added twenty-six compounds to the list of illegal anabolic steroids. Like the prohormones being sold prior to the 2014 ban, these compounds were being sold over-the-counter as prohormones. When the first ban occurred in 2004, supplement companies simply replaced the prohormones with other compounds that were similar in structure but not on the banned list. Hexadrone was one of several chlorinated androstane derivatives introduced into this market vacuum.

While its use in nutritional products became more widespread in recent years, the historical and scientific validation of Hexadrone remains limited. Its commercial career is therefore short, spanning roughly a decade, primarily within underground bodybuilding and performance-enhancement communities rather than mainstream medicine or herbal practice.

3. Key Constituents, Active Compound, and Proposed Mechanisms of Action

Hexadrone is a single synthetic molecule — a synthetic compound classified within the androgenic-anabolic steroid (AAS) family. Unlike multi-ingredient botanical supplements, it contains one defined active entity: the chlorinated androstane compound 6-chloro-androst-4-ene-3-one-17β-ol.

3.1 Receptor-Level Mechanism

Anabolic-androgenic steroids are synthetic derivatives of testosterone. Their anabolic (promoting muscle growth) and androgenic (inducing masculine characteristics) effects result from androgen receptor activation in target tissues. Hexadrone is proposed to act through this same pathway.

Hexadrone is hypothesized to undergo metabolic transformation into dihydrotestosterone (DHT) through 5α-reductase-dependent enzymatic pathways. DHT is a well-characterized androgen with strong affinity for androgen receptors, which are involved in regulating muscle protein synthesis, nitrogen retention, and other anabolic effects in tissue.

A competing view in the literature holds that Hexadrone may act directly rather than requiring conversion. It is described as binding to androgen receptors, promoting protein synthesis and nitrogen retention, and not requiring 5-alpha reduction for activation, exhibiting unique metabolic pathways. The discrepancy between these two mechanistic accounts — requiring versus not requiring enzymatic conversion — has not been resolved in peer-reviewed human pharmacokinetic studies.

3.2 Structural Properties Relevant to Mechanism

The 6-chloro modification completely blocks the aromatase enzyme from acting on the molecule, making it impossible for Hexadrone to convert to estrogen. This property is structurally important: the electron-withdrawing chlorine atom at the 6α position sterically and electronically prevents aromatase-mediated conversion of the A-ring, eliminating the production of estrogenic metabolites. This stands in contrast to most testosterone-derived AAS, which aromatize to varying degrees and can cause estrogen-related side effects such as gynecomastia and water retention.

As a new generation androgen, Hexadrone is characterized as a potent prohormone with strong anabolic and androgenic properties, exhibiting a marketed ratio of 300:1, and it does not cause water retention in the body. It should be noted that this 300:1 anabolic-to-androgenic ratio figure circulates extensively in commercial and user-generated sources but does not appear to derive from published, peer-reviewed assay data specific to Hexadrone.

3.3 Relationship to DHT and 5α-Reductase

In non-human research models, Hexadrone is studied for its potential to act as a prohormone, meaning it may convert into more biologically active steroid hormones, such as dihydrotestosterone (DHT), through metabolic processes. This compound is not naturally occurring in biological systems and is synthesized for research purposes to evaluate its structural analogies to other androgens and its potential anabolic pathways.

4. Scientific Evidence by Area of Use

4.1 Overall State of Clinical Evidence

As an unapproved designer drug, there is zero official clinical research on Hexadrone in humans. All available information is derived from its pharmacology and anecdotal user reports. This is the central and most important evidence statement about Hexadrone: to date, there are few published clinical studies that specifically evaluate the efficacy and safety of Hexadrone in humans. Most available information is derived from anecdotal reports and user testimonials, as well as theoretical assessments based on its chemical structure.

Although Hexadrone has been investigated for its potential influence on muscle hypertrophy, strength parameters, and glycogen retention in controlled laboratory environments, it is important to note that these effects are not verified in human trials, and any claims regarding performance or therapeutic benefits remain unsupported by conclusive scientific data.

Hexadrone is used for weight loss, to improve athletic performance, to reduce sexual problems, and for many other uses, but there is no good scientific evidence to support its use.

4.2 Muscle Hypertrophy and Strength Enhancement

The primary marketed use of Hexadrone is skeletal muscle hypertrophy and strength enhancement. Some preliminary data and animal studies suggest that compounds similar to Hexadrone may exhibit anabolic properties with potentially less androgenic activity, which could translate to muscle-building benefits. However, no randomized controlled trials (RCTs) or prospective cohort studies specifically examining Hexadrone's effects on muscle mass or strength in humans have been identified in the peer-reviewed literature.

The reference in the peer-reviewed MDPI Biomedicines journal (2023) to Hexadrone promoting "muscle mass increase (up to 8–12 pounds)" appears in a descriptive survey of halogenated steroids, citing supplement-industry sources rather than primary clinical trial data. This figure should not be interpreted as a validated clinical outcome.

Evidence strength: Absent (no human clinical trials). Claims rest entirely on in-vitro or animal-model data concerning structurally similar androgens, and on anecdotal user reports.

4.3 Body Composition and Fat Loss

Hexadrone has also been marketed for fat loss and body recomposition, particularly in the context of "cutting" cycles. Hexadrone is used for weight loss, to improve athletic performance, to reduce sexual problems, and for many other uses, but there is no good scientific evidence to support its use. The proposed mechanism — that an androgen with minimal water retention and no aromatization would preferentially spare lean mass during caloric restriction — is pharmacologically plausible by analogy with other non-aromatizing androgens, but has not been tested clinically with Hexadrone as the specific compound.

Evidence strength: Absent for Hexadrone specifically. The broader class of AAS does have clinical evidence for effects on body composition, but those findings cannot be extrapolated as proof of efficacy or safety for any individual novel designer compound.

4.4 Athletic Performance Enhancement

Enhancement of athletic performance — including increased training capacity, faster recovery, and greater strength output — is a claimed benefit. Several side effects are linked with AAS abuse. Only little is known about the pharmacological effects and metabolism of unapproved steroids due to the absence of clinical studies. The general class of AAS has documented effects on performance-related parameters, but the specific contribution of Hexadrone's chlorinated structure to such outcomes in humans has not been studied.

Evidence strength: Absent for Hexadrone. General AAS evidence is not transferable without compound-specific data.

5. Body Systems and Health Areas Associated with Hexadrone

5.1 Skeletal Muscle and Musculoskeletal System

Hexadrone targets androgen receptors in skeletal muscle tissue, consistent with the mechanism of the broader AAS class. Anabolic-androgenic steroids (AASs) are a large group of molecules including endogenously produced androgens, such as testosterone, as well as synthetically manufactured derivatives. AAS use is widespread due to their ability to improve muscle growth for aesthetic purposes and athletes' performance, minimizing androgenic effects.

5.2 Endocrine and Reproductive System

Hexadrone is a type of chemical known as an anabolic steroid and is converted in the body to testosterone and other sex hormones. This conversion places it squarely within the endocrine system. Hexadrone is highly suppressive to the Hypothalamic-Pituitary-Testicular Axis (HPTA).

The broader clinical literature on AAS confirms the mechanism: a well-known complication of AAS use is infertility, due to the suppression of the hypothalamic-pituitary-gonadal (HPG) axis and subsequent suppression of spermatogenesis in the testes. Cessation of AAS use can restore spermatogenesis, but recovery can take several months to years.

For men, AAS exposure commonly suppresses the hypothalamo–pituitary–gonadal axis, leading to hypogonadism and hormonal imbalance that may manifest as reduced libido, erectile dysfunction, gynecomastia, and impaired spermatogenesis ranging from severe oligozoospermia to azoospermia. Recovery after discontinuation is heterogeneous: endocrine parameters frequently normalize earlier than semen parameters, and prolonged/high-dose exposure is associated with delayed or incomplete recovery in a clinically meaningful subset.

For women, the increasing prevalence of AAS among women raises significant health concerns. Prolonged use and/or high doses of AAS are linked to various harmful side effects, including mood changes, psychiatric disorders, voice deepening, clitoromegaly, menstrual irregularities, and cardiovascular complications.

5.3 Cardiovascular System

Chronic supraphysiological AAS exposure is associated with serious cardiovascular consequences, ranging from hypertension and lipid disorders to cardiomyopathy, atherosclerosis, and sudden cardiac death.

Otherwise healthy young athletes abusing AAS may show elevated levels of low-density lipoprotein and low levels of high-density lipoprotein. Although data are conflicting, AAS have also been linked with elevated systolic and diastolic blood pressure and with left ventricular hypertrophy that may persist after AAS cessation. Finally, in small case studies, AAS abuse has been linked with acute myocardial infarction and fatal ventricular arrhythmias.

Chronic supraphysiologic AAS use promotes cardiac injury and adverse cardiac remodeling via oxidative stress, androgen receptor overactivation, RAAS dysregulation, and pro-apoptotic signaling. These changes could lead to hypertension, dyslipidemia and atherosclerosis, myocardial fibrosis and hypertrophy, arrhythmias, heart failure, and kidney injury. Vascular dysfunction, increased arterial stiffness, and a prothrombotic state further compound the cardiovascular risks.

Diagnostic approaches involve biomarker evaluation, echocardiography, and cardiac magnetic resonance imaging, revealing structural and functional cardiac abnormalities such as reduced ejection fraction, concentric hypertrophy, myocardial fibrosis, and impaired diastolic function. Although cessation of AAS use may lead to partial or complete reversal of cardiac dysfunction in some individuals, others may experience irreversible myocardial damage. The reversibility appears to depend on dosage, duration of exposure, and early intervention.

These findings pertain to the AAS class; no Hexadrone-specific cardiovascular studies exist.

5.4 Hepatic System

Hepatotoxicity is one of the most frequent side effects of AAS abuse. AAS-induced hepatotoxicity was hypothesized to be related to oxidative stress in hepatic cells. Hexadrone's marketing often emphasizes its non-methylated structure as a marker of hepatic safety. While it is non-methylated and avoids the C17-AA pathway of liver damage, this does not mean it is liver-safe. All oral steroids must be processed by the liver. Non-methylated compounds can still cause liver strain (hepatotoxicity), potentially through different mechanisms. The long-term effects are unknown.

5.5 Psychological and Behavioral Effects

AASs have side effects involving all organs, tissues and body functions, especially long-term toxicity involving the cardiovascular system and the reproductive system, and their abuse is considered a public health issue. Behavioral changes — including aggression, mood disturbances, and dependence — are documented in the general AAS literature. Side effects reported for Hexadrone include infertility, behavioral changes, hair loss, and breast development (in men).

6. Dosage Forms and Reported Dosages

The appropriate dose of Hexadrone depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for Hexadrone.

The following dosage information is derived from commercial products and user communities, not from clinical trials:

A common dosage range described in user communities is 50–100 mg per day. Cycles typically run for 6–8 weeks.
At least one commercial product (MEDFIT Rx) contains 75 mg of Hexadrone per dose.
The estimated half-life is around 6–8 hours. Due to this short half-life, the total daily dose is commonly divided into 2–3 separate administrations throughout the day to maintain stable blood plasma levels.
A typical Hexadrone cycle described in user communities will last between 4–6 weeks. Those looking for a more advanced cycle will probably opt for a 6–8 week cycle.

No dosing guidance endorsed by a regulatory authority, pharmacopeia, or clinical trial protocol exists. The half-life estimate and all dosage figures cited above are unvalidated in peer-reviewed pharmacokinetic studies.

7. Regulatory Status and Anti-Doping Classification

In the U.S., it is illegal to include anabolic steroids in supplement products. These chemicals are also banned by the World Anti-Doping Agency (WADA).

The Designer Anabolic Steroid Control Act of 2014 (H.R. 4771) is a bill that expanded the list of anabolic steroids regulated by the Drug Enforcement Administration (DEA) to include about two dozen new substances and established new crimes relating to false labeling of steroids. Barack Obama signed the bill into law on December 18, 2014.

Congress intended the DASCA to erase the distinction between the substances once called "prohormones" (steroidal substances unlawfully marketed as dietary supplement products that were either precursors of traditional anabolic steroids or steroidal substances that weren't specially listed in the prior Anabolic Steroid Control Acts) and the substances that were traditionally regarded as anabolic steroids (testosterone, nandrolone, trenbolone, boldenone, etc.).

The 2014 bill states that a drug or hormonal substance derived from, or having a chemical structure substantially similar to, one or more listed anabolic steroids shall be considered an anabolic steroid if it has been created or manufactured with the intent of producing a drug that promotes muscle growth or otherwise causes a pharmacological effect similar to that of testosterone, or has been marketed or promoted in any manner suggesting that consuming it will promote muscle growth or any pharmacological effect similar to that of testosterone.

Like all the anabolic steroids that are already Schedule III drugs, substances covered by the DASCA are illegal not only to sell, but to possess. Possessing any quantity of the new substances on the list is a federal misdemeanor. Distribution and possession with the intent to distribute are felonies.

Criminal penalties can be up to 10 years imprisonment and massive fines (up to $2.5 million on corporations). Civil penalties can be up to $500,000 per product violation for importers, exporters, manufacturers and distributors. Even retailers can be hit with a $25,000 penalty per product violation (and each package size, form, or differently labeled item is a separate product).

The large number of designer steroid findings in dietary supplements and the detection of new compounds combined with legal loopholes for their distribution in many countries show that stricter regulations and better information policy are needed.

Hexadrone is classified under WADA's Prohibited List as an anabolic agent. WADA's Prohibited List class S1.1 covers anabolic androgenic steroids when administered exogenously. The WADA list also prohibits substances "with similar chemical structure or similar biological effect(s)" to explicitly named compounds, meaning that chlorinated androstane derivatives such as Hexadrone fall within the scope of prohibition for all athletes subject to WADA-compliant testing, even if not named individually in every iteration of the list.

8. Safety Considerations and Known Risks

8.1 General Safety Classification

Hexadrone might also be unsafe. When taken by mouth, Hexadrone is possibly unsafe for most people. Side effects include infertility, behavioral changes, hair loss, and breast development (in men). Hexadrone can also lead to liver damage and heart disease.

8.2 Hepatotoxicity

The non-methylated structure of Hexadrone has been widely misrepresented as evidence of hepatic safety. While it is non-methylated and avoids the C17-AA pathway of liver damage, this does not mean it is liver-safe. All oral steroids must be processed by the liver. Non-methylated compounds can still cause liver strain (hepatotoxicity), potentially through different mechanisms. AAS-induced hepatotoxicity was hypothesized to be related to oxidative stress in hepatic cells. Following androgen receptor activation, an increase in reactive oxygen species can be observed due to the increase in mitochondrial β-oxidation. This mechanism would not be avoided simply by the absence of C17-alkylation.

8.3 Cardiovascular Risks

Many studies have linked chronic AAS abuse to a spectrum of cardiovascular complications, initially noted in case reports of young users presenting with unexpected myocardial infarction, stroke, or sudden cardiac death. Subsequent clinical studies and reviews have confirmed associations between long-term AAS use and increased incidence of hypertension, premature coronary artery disease, cardiomyopathy, arrhythmias, thromboembolic events, and heart failure.

From a pathological point of view, supratherapeutic androgen exposure affects the cardiovascular system both directly (via cardiac and vascular androgen receptors) and indirectly (via lipid abnormalities, coagulation changes, and neurohormonal shifts), ultimately promoting atherosclerosis, myocardial fibrosis, and electrical instability.

8.4 HPTA Suppression and Endocrine Disruption

The proven adverse effects of AASs include suppression of the gonadal axis and infertility, hirsutism and defeminization in women, and erythrocytosis.

Androgen abuse consistently produces complete suppression of LH and FSH, marked reductions in sperm concentration and testicular volume, and recovery of endocrine parameters is generally faster than recovery of spermatogenesis. In prospective cohort data, most men with normal baseline gonadal function recovered normal testosterone within three months after stopping AAS, whereas total sperm counts required approximately 48–69 weeks to return to baseline; men with higher cumulative lifetime exposure showed incomplete recovery and biochemical evidence of persistent Leydig cell dysfunction.

8.5 Androgenic Side Effects

Despite the marketed claim of a high anabolic-to-androgenic ratio, Hexadrone remains a chlorinated androstane compound capable of androgenic activity. Side effects attributed to Hexadrone include infertility, behavioral changes, hair loss, and breast development (in men). The latter (gynecomastia) is paradoxically listed despite Hexadrone's non-aromatizing nature; it may occur via rebound estrogen activity following HPTA suppression and endogenous testosterone reduction, or via direct estrogenic activity of metabolites — mechanisms that remain uncharacterized specifically for Hexadrone.

8.6 Female-Specific Risks

Prolonged use and/or high doses of AAS are linked to various harmful side effects in women, including mood changes, psychiatric disorders, voice deepening, clitoromegaly, menstrual irregularities, and cardiovascular complications, prompting medical societies to discourage their widespread use due to insufficient evidence supporting their safety and efficacy.

8.7 Dependence

Over one-third of chronic AAS users develop AAS dependence despite adverse consequences. This risk applies to the broader category of AAS and must be considered relevant to any member of that class, including Hexadrone.

8.8 Interactions

No formal drug-interaction studies for Hexadrone have been published. Based on its AAS classification and mechanism of action, the following interactions are pharmacologically plausible based on the general AAS literature:

Anticoagulants (e.g., warfarin): AAS are known to potentiate the effects of anticoagulants, increasing bleeding risk — a documented interaction for the AAS class generally.
Insulin and antidiabetic agents: AAS can alter glucose metabolism and insulin sensitivity, potentially requiring dose adjustments in diabetic individuals.
Hepatotoxic drugs: Concurrent use of other hepatotoxic substances (including alcohol) is of particular concern given Hexadrone's oral route and hepatic processing. Complete abstinence from alcohol is broadly recommended by those who discuss Hexadrone use.
Hormone-modulating medications: As Hexadrone suppresses endogenous gonadotropins and testosterone, it may interact adversely with fertility treatments, testosterone replacement therapy, or medications for hypogonadism.

None of the above interactions have been tested in Hexadrone-specific clinical studies. They are inferred from the pharmacology of the AAS class.

9. Absence of Clinical Trial Data: A Critical Appraisal

Anabolic-androgenic steroids (AAS) are some of the most common performance enhancing drugs (PED) among society. Despite the broad spectrum of adverse effects and legal consequences, AAS are illicitly marketed and distributed in many countries.

The evidence base for Hexadrone specifically is essentially non-existent in the peer-reviewed clinical literature. The only peer-reviewed publication identified that addresses Hexadrone by name is a 2023 review article in MDPI Biomedicines — Dembitsky VM, "Steroids Bearing Heteroatom as Potential Drugs for Medicine," Biomedicines, 2023, 11(10):2698 — which describes the compound's marketed properties in a survey of halogenated steroids but does not present original clinical data. The paper by Joseph JF and Parr MK, "Synthetic Androgens as Designer Supplements," Current Neuropharmacology, 2015, 13(1):89–100, discusses the broader phenomenon of designer androgens in supplements, including the regulatory and pharmacological challenges they pose, but does not contain human efficacy or safety trial data specific to Hexadrone.